AptarGroup
ATR
120.43
+0.18
+0.15%
AptarGroup
US · ATR
#1713 by market cap
Listed 1970
120.43
+0.18
+0.15%
Live - 5344 symbols - heartbeat 365s ago
· 2026-10-08 07:00
Pre-market
120.43
0.00%
After-hours
120.43
0.00%
- Market cap
- 7.66B
- P/E (TTM)i
- 21.74
- P/Bi
- 2.91
- EPSi
- 5.89
- Div yieldi
- 1.57%
- 52W posi
- 42%
Reader sentiment
Are you bullish or bearish on ATR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.72, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.42% YoY
Margins
- Gross margin
- 37.19%
- Operating margin
- 13.53%
- Net margin
- 10.40%
Key ratios & quality
- Enterprise valuei
- 8.73B
- PEG ratioi
- 1.21
- Altman Z-Scorei
- 3.72
PEG uses trailing P/E against the 3-year net income growth rate (17.96%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.76B | 2.86B | 2.93B | 3.23B | 3.32B | 3.49B | 3.58B | 3.78B |
| Gross profit | 951.80M | 1.04B | 1.09B | 1.16B | 1.16B | 1.26B | 1.36B | 1.40B |
| Selling & admin expenses | 429.96M | 454.62M | 500.23M | 551.24M | 544.26M | 565.78M | 582.23M | 606.50M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 350.10M | 392.17M | 365.99M | 370.59M | 385.87M | 449.02M | 509.50M | 510.88M |
| Pretax profit | 266.02M | 342.07M | 301.16M | 321.66M | 334.70M | 374.83M | 469.77M | 491.38M |
| Tax | 71.25M | 99.84M | 87.07M | 78.02M | 95.15M | 90.65M | 95.59M | 98.88M |
| Net profit | 194.77M | 242.23M | 214.09M | 243.64M | 239.56M | 284.18M | 374.18M | 392.50M |
| Basic EPS | 3 | 4 | 3 | 4 | 4 | 4 | 6 | 6 |
| Diluted EPS | 3.00 | 3.66 | 3.21 | 3.61 | 3.59 | 4.25 | 5.53 | 5.89 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 887.31M | 966.01M | 961.13M | 962.74M | 982.87M | 1.03B |
| Gross profit | 336.41M | 367.02M | 363.09M | 338.22M | 351.91M | 365.52M |
| Selling & admin expenses | 155.28M | 151.14M | 148.76M | 151.32M | 167.60M | 157.74M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 115.49M | 145.97M | 139.09M | 110.32M | 108.58M | 128.14M |
| Pretax profit | 106.02M | 139.71M | 154.13M | 91.52M | 93.77M | 115.05M |
| Tax | 27.35M | 27.98M | 26.30M | 17.25M | 21.00M | 27.04M |
| Net profit | 78.66M | 111.73M | 127.83M | 74.27M | 72.77M | 88.01M |
| Basic EPS | 1 | 2 | 2 | 1 | 1 | 1 |
| Diluted EPS | 1.17 | 1.67 | 1.92 | 1.13 | 1.12 | 1.36 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.33B | 1.29B | 1.37B | 1.36B | 1.43B | 1.55B | 1.48B | 1.89B |
| Cash & ST investments | 261.82M | 241.97M | 300.38M | 123.67M | 141.73M | 223.64M | 226.18M | 409.53M |
| Inventory | 381.11M | 375.80M | 379.38M | 441.46M | 486.81M | 513.05M | 461.81M | 537.85M |
| Total assets | 3.38B | 3.56B | 3.99B | 4.14B | 4.20B | 4.45B | 4.43B | 5.25B |
| Total current liabilities | 689.17M | 683.28M | 780.33M | 982.49M | 917.18M | 1.25B | 1.07B | 1.17B |
| Short-term debt | 163.97M | 110.25M | 117.87M | 289.63M | 122.79M | 458.22M | 338.29M | 343.53M |
| Long-term debt | 1.13B | 1.09B | 1.05B | 907.02M | 1.05B | 681.19M | 688.07M | 1.14B |
| Total liabilities | 1,954,864,000.00 | 1,989,867,000.00 | 2,139,268,000.00 | 2,156,764,000.00 | 2,135,254,000.00 | 2,130,592,000.00 | 1,946,354,000.00 | 2,540,494,000.00 |
| Total equity | 1.42B | 1.57B | 1.85B | 1.98B | 2.07B | 2.32B | 2.49B | 2.71B |
| Retained earnings | 1.37B | 1.52B | 1.64B | 1.79B | 1.93B | 2.11B | 2.37B | 2.64B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.51B | 1.66B | 1.78B | 1.89B | 1.77B | 1.83B |
| Cash & ST investments | 136.82M | 169.77M | 264.82M | 409.53M | 229.48M | 197.27M |
| Inventory | 483.52M | 527.42M | 547.30M | 537.85M | 551.48M | 580.14M |
| Total assets | 4.53B | 4.87B | 5.10B | 5.25B | 5.10B | 5.13B |
| Total current liabilities | 1.21B | 1.37B | 1.50B | 1.17B | 1.06B | 1.14B |
| Short-term debt | 445.39M | 551.52M | 654.57M | 343.53M | 222.17M | 249.24M |
| Long-term debt | 561.17M | 535.05M | 546.02M | 1.14B | 1.14B | 1.12B |
| Total liabilities | 1,975,554,000.00 | 2,147,567,000.00 | 2,288,780,000.00 | 2,540,494,000.00 | 2,423,532,000.00 | 2,458,769,000.00 |
| Total equity | 2.55B | 2.72B | 2.81B | 2.71B | 2.67B | 2.67B |
| Retained earnings | 2.42B | 2.50B | 2.60B | 2.64B | 2.68B | 2.74B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 313.63M | 514.46M | 570.15M | 363.44M | 478.62M | 575.24M | 643.41M | 570.00M |
| Depreciation & amortization | 171.75M | 194.55M | 220.30M | 234.85M | 233.71M | 248.59M | 263.78M | 287.36M |
| Free cash flow | 101.77M | 267.38M | 318.11M | 55.51M | 163.00M | 256.84M | 349.22M | 294.56M |
| Dividends paid | -82.35M | -90.21M | -92.66M | -98.51M | -99.46M | -103.68M | -114.06M | -120.78M |
| Stock buybacks / issuance | -61.69M | -86.50M | 0 | -78.15M | -92.13M | -47.55M | -68.64M | -365.01M |
| Ending cash balance | 266.82M | 246.97M | 304.97M | 122.93M | 142.73M | 224.14M | 224.34M | 404.85M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 82.74M | 125.96M | 177.61M | 183.69M | 118.69M | 103.49M |
| Depreciation & amortization | 65.65M | 69.90M | 75.23M | 76.58M | 75.73M | 79.64M |
| Free cash flow | 23.41M | 61.00M | 114.00M | 96.16M | 52.71M | 45.62M |
| Dividends paid | -29.92M | -29.72M | -29.65M | -31.50M | -30.92M | -30.61M |
| Stock buybacks / issuance | -80.00M | -70.00M | -40.01M | -175.00M | -99.97M | -50.00M |
| Ending cash balance | 125.84M | 161.73M | 257.06M | 404.85M | 224.95M | 192.83M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 14.24 | 16.18 | 12.51 | 12.78 | 11.90 | 13.05 | 15.68 | 15.28 |
| ROA %i | 5.98 | 6.98 | 5.67 | 6.00 | 5.74 | 6.57 | 8.43 | 8.11 |
| ROIC %i | 8.08 | 9.55 | 8.04 | 8.40 | 8.22 | 9.22 | 11.36 | 10.99 |
| 5-year avg ROE %i | 16.44 | 16.70 | 15.67 | 14.68 | 13.52 | 13.28 | 13.18 | 13.74 |
| EBIT margin %i | 10.80 | 13.20 | 11.42 | 10.91 | 11.30 | 11.91 | 14.34 | 14.41 |
| FCF / sales %i | 3.68 | 9.35 | 10.86 | 1.72 | 4.91 | 7.36 | 9.75 | 7.80 |
| Current ratioi | 1.93 | 1.89 | 1.75 | 1.38 | 1.56 | 1.24 | 1.38 | 1.62 |
| Quick ratioi | 1.21 | 1.17 | 1.11 | 0.81 | 0.89 | 0.72 | 0.83 | 1.04 |
| Debt / assetsi | 38.19 | 35.12 | 30.70 | 30.05 | 28.98 | 26.61 | 24.28 | 29.15 |
| LT debt / equityi | 79.15 | 72.57 | 59.84 | 48.49 | 53.34 | 31.49 | 29.85 | 44.50 |
| Interest coveragei | 9.15 | 10.64 | 10.06 | 11.62 | 9.20 | 10.27 | 11.70 | 10.32 |
| Revenue CAGR (3Y) %i | 6.06 | 7.05 | 5.86 | 5.29 | 5.12 | 5.99 | 3.55 | 4.37 |
| Net income CAGR (3Y) %i | -0.78 | 5.61 | -0.92 | 7.82 | -0.40 | 9.95 | 15.34 | 17.96 |
| FCF CAGR (3Y) %i | -16.44 | 11.32 | 23.69 | -18.29 | -15.21 | -6.88 | 84.61 | 21.80 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 15.15 | 15.36 | 15.80 | 15.28 | 14.97 | 13.61 |
| ROA %i | 8.26 | 8.40 | 8.62 | 8.11 | 8.03 | 7.25 |
| ROIC %i | 11.15 | 11.39 | 11.68 | 10.99 | 11.10 | 10.22 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 14.53 | 14.92 | 15.37 | 14.41 | 13.88 | 13.17 |
| FCF / sales %i | 10.01 | 9.46 | 8.36 | 7.80 | 8.36 | 7.84 |
| Current ratioi | 1.25 | 1.21 | 1.19 | 1.62 | 1.66 | 1.61 |
| Quick ratioi | 0.73 | 0.71 | 0.71 | 1.04 | 1.00 | 0.96 |
| Debt / assetsi | 23.36 | 23.35 | 24.50 | 29.15 | 27.65 | 27.50 |
| LT debt / equityi | 24.12 | 21.66 | 21.49 | 44.50 | 45.16 | 44.22 |
| Interest coveragei | 11.46 | 11.75 | 11.95 | 10.32 | 9.21 | 8.16 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Pharma is the largest reported line at 44.65% of revenue, across 4 reported segments.
- No single line clears half of revenue; Beauty is next at 36.77%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Pharma44.65%
Beauty36.77%
Closures19.73%
Quote time 2026-10-08 07:00:15 · For reference only, not investment advice and not tailored to your situation.